Weight Loss Injections 2026: Complete Guide to GLP-1s, Tirzepatide & Beyond
Injectable weight loss medications have revolutionized obesity treatment. Here's the complete breakdown of all available options: semaglutide, tirzepatide, liraglutide, retatrutide, and emerging peptides. Compare efficacy, costs, side effects, and how to access them.
The Weight Loss Injection Revolution
Injectable medications for weight loss have transformed from niche treatments to mainstream options. Unlike restrictive diets, these medications work by suppressing appetite and improving satiety through biological mechanisms.
Key facts:
- GLP-1 agonists are the most established class, with 15+ years of safety data from diabetes treatment
- Tirzepatide (dual GLP-1/GIP agonist) offers stronger weight loss than GLP-1s alone
- Injectable peptides represent a paradigm shift: medication-assisted weight loss is now first-line therapy for obesity
- Access has expanded dramatically through telehealth, making treatment more accessible than ever
- Costs remain high without insurance, but generic options and insurance coverage have improved availability
Comprehensive Comparison of All Weight Loss Injections
| Drug Name | Generic | Class | Avg Weight Loss | Monthly Cost |
|---|---|---|---|---|
| Semaglutide (Wegovy) | Semaglutide | GLP-1 | 15–18% | $900–$1,500 |
| Semaglutide (Ozempic) | Semaglutide | GLP-1 (diabetes) | 10–18%* | $890–$1,200 |
| Tirzepatide (Zepbound) | Tirzepatide | GLP-1/GIP | 22% | $1,100–$1,500 |
| Tirzepatide (Mounjaro) | Tirzepatide | GLP-1/GIP (diabetes) | 22%* | $1,000–$1,400 |
| Liraglutide (Saxenda) | Liraglutide | GLP-1 | 8–10% | $1,200–$1,700 |
| Retatrutide (Pending) | Retatrutide | GLP-1/GIP/GCG | 24% (trial data) | $1,500+ (estimated) |
*Off-label use for weight loss. Approved for diabetes but used off-label by weight loss clinics.
Semaglutide (Ozempic, Wegovy, Rybelsus)
Semaglutide is a GLP-1 receptor agonist originally approved for type 2 diabetes (Ozempic). Wegovy is the same drug at higher doses approved specifically for weight loss. Rybelsus is the oral formulation.
Mechanism: GLP-1 agonists mimic glucagon-like peptide-1, a hormone that regulates appetite, blood sugar, and gastric emptying. Semaglutide slows stomach emptying and increases satiety, reducing hunger and food intake.
Dosing for weight loss (Wegovy): 0.25 mg weekly (weeks 1–4), 0.5 mg weekly (weeks 5–8), 1.0 mg weekly (weeks 9–12), 1.7 mg weekly (week 13+), 2.4 mg weekly (maintenance). Full titration takes 16 weeks.
Expected weight loss: 15–18% of body weight (STEP 1 trial). For a 200-pound person, that's 30–36 pounds over 68 weeks.
Frequency: Once-weekly injection (subcutaneous, usually in the abdomen, thigh, or upper arm).
Cost: Ozempic (diabetes): $890–$1,200/month. Wegovy (weight loss): $900–$1,500/month. With insurance, often $25–$100/month copay.
Side effects: Nausea (70%), constipation (23%), vomiting (5%). Most side effects peak during titration and improve over weeks 5–8.
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide is a dual GLP-1/GIP receptor agonist. Unlike semaglutide (GLP-1 only), tirzepatide activates both GLP-1 and GIP receptors, offering superior weight loss.
Mechanism: GLP-1 suppresses appetite; GIP enhances insulin secretion and energy expenditure. The dual action produces greater weight loss than GLP-1 alone.
Dosing for weight loss (Zepbound): 2.5 mg weekly (weeks 1–4), 5.0 mg weekly (weeks 5–8), 7.5 mg weekly (weeks 9–12), 10.0 mg weekly (weeks 13–16), 15.0 mg weekly (maintenance).
Expected weight loss: 22% of body weight at highest dose (SURPASS 2 trial). For a 200-pound person, that's 44 pounds.
Frequency: Once-weekly injection.
Cost: Mounjaro (diabetes): $1,000–$1,400/month. Zepbound (weight loss): $1,100–$1,500/month. With insurance, $25–$150/month copay.
Side effects: Similar to semaglutide but potentially more intense (nausea, vomiting more common). Gastrointestinal side effects peak during dose escalation.
Advantage over semaglutide: Stronger weight loss, once-weekly dosing, potential for better appetite suppression.
Liraglutide (Saxenda, Victoza)
Liraglutide is an older GLP-1 agonist with a longer track record but lower efficacy than semaglutide.
Mechanism: GLP-1 receptor agonist (same class as semaglutide but different structure).
Dosing: Daily injections starting at 0.6 mg, titrating to 3.0 mg daily. Requires daily injections (versus weekly for semaglutide/tirzepatide).
Expected weight loss: 8–10% of body weight. Significantly lower than semaglutide or tirzepatide.
Cost: $1,200–$1,700/month.
Side effects: Similar GI side effects; same nausea, constipation, vomiting.
Advantage: Longer safety history. Disadvantage: less effective, requires daily injections.
Retatrutide (Emerging Triple Agonist)
Retatrutide is the next generation of weight loss injectables. It's a triple GLP-1/GIP/GCG (glucagon) receptor agonist.
Mechanism: Activates three metabolic pathways: appetite suppression (GLP-1), energy expenditure (GIP, glucagon), and metabolic rate elevation (glucagon).
Trial data: SURMOUNT trials show 24–28% weight loss at highest doses. Even stronger than tirzepatide.
Status (2026): Under FDA review for weight loss approval. Expected FDA decision in late 2024 or early 2025. Not yet widely available.
Expected cost: Likely $1,500–$2,000/month, similar to or slightly higher than tirzepatide.
Side effects: Similar GI side effects to tirzepatide. Potential for more prominent nausea/vomiting during dose escalation.
AOD-9604 and Other Emerging Peptides
AOD-9604 is a growth hormone releasing peptide fragment (fragment 176–191 of human growth hormone) with thermogenic and lipolytic properties.
Mechanism: Increases fat mobilization and thermogenesis without stimulating growth hormone secretion.
Availability: Primarily available through research peptide suppliers and compounding pharmacies. Limited clinical evidence; not FDA-approved for weight loss.
Cost: $100–$300/month (significantly cheaper than GLP-1s).
Expected weight loss: 5–15 lbs over 12 weeks (modest compared to GLP-1s). Limited human trial data.
Status: Experimental. Users often combine AOD-9604 with GLP-1s for potential synergy, though evidence is anecdotal.
How Weight Loss Injections Work: The Biology
All injectable weight loss drugs work through appetite suppression and metabolic effects:
1. Appetite suppression: GLP-1 and tirzepatide activate brain centers that regulate hunger. Appetite decreases dramatically.
2. Gastric emptying slows: Food moves through your stomach slower, increasing satiety and fullness after meals.
3. Blood sugar stabilization: Steadier blood glucose reduces energy crashes and cravings.
4. Metabolic rate: Some evidence suggests modest increases in resting metabolic rate, though effects are modest.
5. Gut signaling: Changes in hormones that communicate fullness to the brain.
Factors Affecting Weight Loss Efficacy
Not everyone loses the same amount of weight on the same medication. Several factors influence response:
- Baseline weight: Higher baseline weight often correlates with greater absolute weight loss
- Adherence: Weekly injections must be consistent; skipped doses reduce efficacy
- Diet quality: Medications suppress appetite but don't prevent poor food choices. Healthy eating accelerates loss
- Exercise: Physical activity amplifies weight loss results
- Sleep: Poor sleep reduces weight loss efficacy
- Genetics: Some people are naturally responders; others show modest response to GLP-1s
- Dose: Higher doses produce greater weight loss (up to a plateau)
- Duration: Efficacy increases over 3–6 months; continued treatment maintains results
Side Effects Comparison
| Side Effect | Semaglutide | Tirzepatide | Liraglutide |
|---|---|---|---|
| Nausea | 70% | 75% | 68% |
| Vomiting | 5–10% | 10–15% | 4–8% |
| Constipation | 23% | 28% | 20% |
| Diarrhea | 15% | 12% | 18% |
How to Get Weight Loss Injections
Option 1: Traditional Doctor Visit
Establish care with a primary care physician or obesity medicine specialist. Request a prescription for semaglutide, tirzepatide, or liraglutide. Typical timeline: 2–4 weeks (requires multiple visits for labs, evaluation, prescription).
Option 2: Telehealth GLP-1 Services
Companies like Ro, Hims, Noom, WeightWatchers offer telehealth GLP-1 prescriptions. Process: online consultation (1–2 days), lab work optional, prescription issued within 3–7 days. Cost: $200–$500/month depending on medication choice and insurance.
Option 3: Weight Loss Clinics
Specialized weight loss centers offer GLP-1s alongside nutrition counseling and exercise programs. More expensive ($100–$300 consultation fee plus medication cost) but include comprehensive support.
Option 4: Compounding Pharmacies
Some compounding pharmacies prepare semaglutide from raw pharmaceutical ingredients. Cost: $200–$400/month, often without insurance requirement. Quality and sterility vary; use only licensed, verified compounders.
Insurance Coverage and Cost Savings
Coverage varies by insurance plan and indication:
- For diabetes: Ozempic, Mounjaro, Saxenda typically covered with $25–$50 copay
- For weight loss: Coverage more variable. Some plans cover Wegovy/Zepbound; others don't. Prior authorization often required
- Without insurance: Manufacturer patient assistance programs, GoodRx discounts, or telehealth services can reduce out-of-pocket costs
Related Guides
Semaglutide efficacy, dosing, and off-label use for non-diabetics.
Mounjaro for Weight LossTirzepatide comparison to semaglutide and expected weight loss outcomes.
Wegovy Side EffectsComplete list of side effects, management strategies, and when to call your doctor.
Zepbound Cost and PricingTirzepatide pricing, insurance coverage, and cost reduction strategies.
Retatrutide: Next-Gen GLP-1Triple agonist efficacy, trial results, and expected availability.
Peptides for Weight LossEmerging peptides and their role in weight management.
Frequently Asked Questions
Tirzepatide (Mounjaro/Zepbound) shows the highest average weight loss: 22% of body weight over 52 weeks at the highest dose. Semaglutide (Wegovy) averages 15–18% weight loss. However, individual response varies. Some people respond better to semaglutide than tirzepatide and vice versa. Efficacy also depends on dose, duration, lifestyle factors, and genetics.
Retail costs: Ozempic $890–$1,200/month, Wegovy $900–$1,500/month, Mounjaro/Zepbound $1,100–$1,500/month, Saxenda $1,200–$1,700/month. With insurance, copays are typically $25–$200/month. Telehealth providers (Ro, Hims) offer lower costs ($200–$400/month) but may use compounded semaglutide. Always verify coverage with your insurance.
Options include: (1) Traditional doctor visit with prescription, (2) Telehealth GLP-1 services (Ro, Hims, WeightWatchers), (3) Specialized weight loss clinics, (4) Compounding pharmacies. Telehealth is fastest (often 3–7 days). Traditional routes require established care. Verify your insurance covers the specific medication and provider.
Most people notice appetite suppression within 3–5 days of the first injection. Significant weight loss (5+ lbs) appears after 3–4 weeks. Maximum efficacy requires 8–12 weeks of consistent dosing. GLP-1s are not overnight solutions; they work gradually by reducing hunger.
Switching is possible but requires medical supervision. Generally, you stop one GLP-1 and start another. Don't take two simultaneously—it increases side effect risk. Some physicians trial different GLP-1s to find the best fit. Switching requires at least 1 week of washout (stopping the first medication before starting the next).
Most people regain some weight after stopping GLP-1s. Studies show 30–50% of lost weight returns within 1 year of discontinuation. Permanent weight loss requires sustained lifestyle changes (diet, exercise) or ongoing medication. This is why GLP-1s are considered long-term treatments, not short-term solutions.